🇺🇸 FDA
Patent

US 9273136

Fully human anti-human NKG2D monoclonal antibodies

granted A61KA61K2039/505A61P

Quick answer

US patent 9273136 (Fully human anti-human NKG2D monoclonal antibodies) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61P, A61P29/00, A61P31/00